---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-22-000097"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2022-06-29T23:59:59+00:00"
generated_at: "2026-06-24T22:30:58.535926+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Ligand appoints Jason Haas to Board of Directors, effective June 29, 2022

## Summary
- Jason Haas appointed to Board and Audit Committee; brings 30+ years healthcare investment banking experience.
- Haas currently CFO of Syros Pharmaceuticals; previously Co-Head Americas Healthcare Banking at Barclays.
- Received 1,750 RSUs and options for 5,907 shares at $88.52, vesting over three years.
- Chairman Kozarich cites Haas' 10+ years as Ligand financial advisor; appointment ahead of OmniAb spin-off.

## SEC filing metadata
- accession: 0000886163-22-000097
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2022-06-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616322000097/0000886163-22-000097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616322000097/lgnd-20220629.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-22-000097
- JSON: https://secwatch.observer/filing/0000886163-22-000097.json
- Plain text: https://secwatch.observer/filing/0000886163-22-000097.txt

## Key facts
- Executive change
  Jason Haas was appointed as Director at LIGAND PHARMACEUTICALS INC.
  - Action: appointed
  - Role: Director
  source text: Effective as of June 29, 2022, the Board of Directors of Ligand Pharmaceuticals Incorporated (the “Company”) appointed Jason Haas to the Company’s Board of Directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/886163/000088616322000097/0000886163-22-000097-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.